Skip to main content

Repligen Corp

RGEN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000730272

In the last 90 days, Repligen Corp insiders filed 0 open-market purchases and 5 sales; 481 institutions reported holding it in 13F filings for Q2 2026, worth $9.00B in total; 3 superinvestors hold it, including Maverick Capital and Duquesne Family Office.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Repligen Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
5 filings
2 insiders, $5.00M in total
Insiders trading
2
Net value
−$5.00M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Repligen Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Repligen Corp
NameTitleLast reported holdingLast filingFilings, past year
Loeillot OlivierChief Executive Officer48,369Sep 25, 20269
Hughes ViolettaCHIEF ACCOUNTING OFFICER6,331Sep 2, 20261
Garland Jason KCFO18,829Jul 17, 20264
Muir Glenn PDirector40,051May 18, 20263
Dawes Karen ADirector92,816May 18, 20262
Barthelemy NicolasDirector5,436May 18, 20261
Madaus Martin DDirector6,581May 18, 20261
Eglinton Manner CarrieDirector5,461May 18, 20261
Konstantinov KonstantinDirector3,889May 18, 20261
Mhatre RohinDirector5,014May 18, 20261
Pax MargaretDirector3,011May 18, 20261
Douglass Brian RobbCHIEF PRODUCT OFFICER7,985May 8, 20263
Kuriyel RalfSenior VP, R&D20,062Mar 23, 20263
Bylund JamesChief Operating Officer25,423Mar 23, 20264
Hunt AnthonyDirector89,062Mar 3, 20264
Gebski ChristineSee Remarks27,419May 15, 20240
Snodgres JonChief Financial Officer37,381May 16, 20230
Ryan Thomas F JrDirector1,457Mar 2, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 14, 2025 (view filing)Nov 131 dayHunt AnthonyDirectorSSale−20.0K$154.61−$3.09M−19.9%80.7K after7 lots
Nov 19, 2025 (view filing)Nov 181 dayBylund JamesChief Operating OfficerSSale−2.19K$151.21−$331.3K−9.2%21.5K after
Nov 26, 2025 (view filing)Nov 251 dayLoeillot OlivierChief Executive OfficerSSale−7.04K$170.00−$1.20M−16.4%35.9K after10b5-1
Dec 18, 2025 (view filing)Dec 171 dayDawes Karen ADirectorSSale−275$161.00−$44.3K−0.3%91.8K after
Apr 22, 2026 (view filing)Apr 211 dayLoeillot OlivierChief Executive OfficerSSale−3.83K$140.00−$536.5K−6.6%54.2K after10b5-1
Jun 26, 2026 (view filing)Jun 251 dayGarland Jason KCFOSSale−733$145.00−$106.3K−3.6%19.4K after10b5-1
Jul 17, 2026 (view filing)4:40 PM ETJul 161 dayGarland Jason KCFOSSale−530$150.00−$79.5K−2.7%18.8K after10b5-1
Aug 21, 2026 (view filing)4:06 PM ETAug 201 dayLoeillot OlivierChief Executive OfficerSSale−5.43K$180.00−$976.7K−9.1%54.2K after10b5-1
Sep 8, 2026 (view filing)4:13 PM ETSep 44 daysLoeillot OlivierChief Executive OfficerSSale−3.04K$165.90−$503.5K−5.9%48.4K after10b5-1
Sep 22, 2026 (view filing)4:07 PM ETSep 211 dayLoeillot OlivierChief Executive OfficerSSale−5.43K$180.00−$976.7K−10.1%48.4K after10b5-1
Sep 25, 2026 (view filing)4:09 PM ETSep 241 dayLoeillot OlivierChief Executive OfficerSSale−12.9K$190.00−$2.46M−21.1%48.4K after2 lots10b5-1